Pyrazolopyrimidines suitable for the treatment of cancer diseases
申请人:Schering Corporation
公开号:EP2194058A1
公开(公告)日:2010-06-09
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
into amides 10 was developed. The key step of the synthesis was the stereoselective intramolecular opening of the epoxides 11a–d leading to the exo-configured 8-hydroxymorphans 12a–d. The configuration of the exo-configured hydroxymorphan 12d bearing the κ- and σ-pharmacophoric 3,4-dichlorophenylacetyl moiety was inverted by oxidation and stereoselective reduction. An X-ray crystal structure analysis